SCHEMBL2903282

SCHEMBL2903282

COc1cc(C=C(C(=O)OCCC(C)C)C(=O)OCCC(C)C)cc(OC)c1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
PKM P14618 2/20 0.60
KDM4E B2RXH2 2/20 0.60
ALDH1A1 P00352 2/20 0.60
GAA P10253 2/20 0.60
ALOX5 P09917 4/20 0.46
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2B6 P20813 1/20 0.43
MET P08581 4/20 0.43
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
LMNA P02545 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
PTP4A3 O75365 2/20 0.41
PTP4A2 Q12974 2/20 0.41
PTP4A1 Q93096 2/20 0.41
MAPT P10636 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2211610 0.94 KDM4E (0.56) KMT2APKMKDM4EALDH1A1GAA
SCHEMBL2905466 0.90 ALDH1A1 (0.50) KMT2APKMKDM4EALDH1A1GAA
SCHEMBL934472 0.86 MAPT (0.59) KMT2APKMKDM4EALDH1A1GAA
SCHEMBL2212255 0.86 KDM4E (0.48) KMT2APKMKDM4EALDH1A1GAA
SCHEMBL2269143 0.85 KMT2A (0.47) KMT2APKMKDM4EALDH1A1GAA
SCHEMBL23407467 0.85 ALOX5 (0.62) KMT2APKMKDM4EGAAALOX5
SCHEMBL23407458 0.82 ALOX5 (0.52) KMT2APKMKDM4EALDH1A1ALOX5
SCHEMBL2897877 0.81 KMT2A (0.57) KMT2APKMKDM4EALDH1A1GAA
SCHEMBL23407460 0.81 ALOX5 (0.51) KMT2AKDM4EALDH1A1ALOX5CYP1A2
SCHEMBL2216850 0.80 MAPT (0.66) KMT2APKMKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12453682-B2 Composition comprising at least 5% by weight of titanium oxides, an α-cyanodiphenylacrylate derivative and a 4-hydroxybenzylidenemalonate or 4-hydroxycinnamate derivative L'ORÉAL (FR) 2025-10-28 US claimed
US-20230044544-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN a-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2023-02-09 US claimed
EP-4076677-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN A-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2022-10-26 EP claimed
WO-2021122039-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN A-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2021-06-24 WO claimed
EP-1635777-B1 PHOTOSTABLE ORGANIC SUNSCREEN COMPOSITION MERCK PATENT GMBH (DE) 2012-06-06 EP claimed
EP-1747773-B1 Photostable organic sunscreen compositions with antioxidant properties MERCK PATENT GMBH (DE) 2010-08-04 EP claimed
EP-1406582-B1 PHOTOSTABLE ORGANIC SUNSCREEN COMPOUNDS WITH ANTIOXIDANT PROPERTIES AND COMPOSITIONS OBTAINED THEREFROM MERCK PATENT GMBH (DE) 2006-10-25 EP claimed
CN-1798538-A Photostable organic sunscreen composition MERCK PATENT GMBH (DE) 2006-07-05 CN claimed
US-12453682-B2 Composition comprising at least 5% by weight of titanium oxides, an α-cyanodiphenylacrylate derivative and a 4-hydroxybenzylidenemalonate or 4-hydroxycinnamate derivative L'ORÉAL (FR) 2025-10-28 US disclosed
US-20230044544-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN a-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2023-02-09 US disclosed
EP-4076677-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN A-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2022-10-26 EP disclosed
WO-2021122039-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN A-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2021-06-24 WO disclosed
CN-104869974-A Compositions and/or articles with improved solubility of solid active substances PROCTER & GAMBLE 2015-08-26 CN disclosed
CN-104302268-A Personal care compositions with improved solubility of a solid cosmetic active substance PROCTER & GAMBLE 2015-01-21 CN disclosed
CN-104144676-A Sunscreen compositions comprising UV composites PROCTER & GAMBLE 2014-11-12 CN disclosed
CN-104039396-A PERSONAL CARE COMPOSITIONS COMPRISING A pH TUNEABLE GELLANT AND METHODS OF USING PROCTER & GAMBLE 2014-09-10 CN disclosed
CN-103930167-A Personal care compositions comprising a di-amido gellant and methods of using PROCTER & GAMBLE 2014-07-16 CN disclosed
CN-103857376-A Personal care compositions with improved solubility of a solid UV active PROCTER & GAMBLE 2014-06-11 CN disclosed
CN-103619308-A Personal care compositions comprising shaped abrasive particles PROCTER & GAMBLE 2014-03-05 CN disclosed
CN-1798538-A Photostable organic sunscreen composition MERCK PATENT GMBH (DE) 2006-07-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230044544-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN a-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE HAAO, HAO2, HPD KMT2A 1848/4885PKM 2334/4885KDM4E 470/4885
US-12453682-B2 Composition comprising at least 5% by weight of titanium oxides, an α-cyanodiphenylacrylate derivative and a 4-hydroxybenzylidenemalonate or 4-hydroxycinnamate derivative HAAO, HPD, P4HA1 KMT2A 2101/4885PKM 2271/4885KDM4E 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.